Database : MEDLINE
Search on : Pleural and Neoplasms [Words]
References found : 21903 [refine]
Displaying: 1 .. 10   in format [Detailed]

page 1 of 2191 go to page                         

  1 / 21903 MEDLINE  
              next record last record
select
to print
Photocopy
Full text

[PMID]: 29505507
[Au] Autor:Wang CG; Zeng DX; Huang JA; Jiang JH
[Ad] Address:Department of Respiratory and Critical Care, First Affiliated Hospital of Soochow University, Suzhou, P.R. China.
[Ti] Title:Effective assessment of low times MET amplification in pleural effusion after epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) acquired resistance: Cases report.
[So] Source:Medicine (Baltimore);97(1):e9021, 2018 Jan.
[Is] ISSN:1536-5964
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:RATIONALE: The mechanism of the first-generation epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) acquired resistance included T790M mutation, cellular-mesenchymal to epithelial transition factor (MET) or EGFR amplification, PIK3CA mutation, and transformation to small cell lung cancer. MET amplification accounted for only about 5% of the resistance cases. PATIENTS CONCERNS: Few report detected MET amplification in pleural effusion. Here, we reported 2 lung adenocarcinoma cases with MET amplification in pleural effusion rapidly responded to crizotinib after EGFR-TKIs acquired resistance. DIAGNOSES: Biopsy via bronchoscopy, next-generation sequencing (NGS) in pleural effusion. INTERVENTIONS: EGFR-TKIs (Icotinib), MET inhibitor crizotinib. OUTCOMES: After a progression-free survival of 9 months and 23months, respectively, both cases progressed accompanying with pleural effusion. Results of NGS in pleural effusion showed MET amplification (2-3 times) in both cases. The 2 patients were treated with a MET inhibitor crizotinib and rapidly responded. CONCLUSION: MET amplification in pleural effusion could predict a perfect response to crizotinib after EGFR-TKIs acquired resistance, even only a low times gene amplification.
[Mh] MeSH terms primary: Adenocarcinoma/genetics
Drug Resistance, Neoplasm/genetics
Lung Neoplasms/genetics
Pleural Effusion, Malignant/metabolism
Proto-Oncogene Proteins c-met/genetics
[Mh] MeSH terms secundary: Adenocarcinoma/drug therapy
Aged
Female
Gene Amplification
Humans
Lung Neoplasms/drug therapy
Male
Middle Aged
Protein Kinase Inhibitors/therapeutic use
Proto-Oncogene Proteins c-met/metabolism
Pyrazoles/therapeutic use
Pyridines/therapeutic use
[Pt] Publication type:CASE REPORTS; JOURNAL ARTICLE
[Nm] Name of substance:0 (Protein Kinase Inhibitors); 0 (Pyrazoles); 0 (Pyridines); 53AH36668S (crizotinib); EC 2.7.10.1 (MET protein, human); EC 2.7.10.1 (Proto-Oncogene Proteins c-met)
[Em] Entry month:1803
[Cu] Class update date: 180309
[Lr] Last revision date:180309
[Js] Journal subset:AIM; IM
[Da] Date of entry for processing:180306
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009021

  2 / 21903 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy

[PMID]: 29519996
[Au] Autor:AlAmodi AA; Farhoud MH; Mohammad N; Alatassi R; Alolayet D; AlQeshtaini N; AlMamlouk R; Ahmed MH; Ashour M; Kayyali SS; AlShammari A
[Ad] Address:College of Medicine, Alfaisal University, Riyadh, Saudi Arabia.
[Ti] Title:Sterile Bronchopleural Fistula Following Surgical Removal of Primary Lung Leiomyoma Inducing Secondary Hypertrophic Osteoarthropathy.
[So] Source:Am J Case Rep;19:267-271, 2018 Mar 09.
[Is] ISSN:1941-5923
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:BACKGROUND Leiomyomas are benign neoplasms of the smooth muscle. When found in the pulmonary system, a rare occurrence, leiomyomas can result in hypertrophic osteoarthropathy, or significant clubbing, associated with proliferation of long bone periosteum. Bronchopulmonary fistulas, or communications between the bronchial tree and pleural space, are an uncommon postoperative complication of pneumonectomies. Even more infrequent is the presence of a bronchopulmonary fistula that is determined to be sterile. CASE REPORT The patient presented in the current case report is a 40-year-old previously healthy woman who presented with a 5-year history of chronic cough, right-sided chest discomfort, and dyspnea associated with back pain, and lower leg pain. The CT scan performed on the patient revealed a mass originating from the right lower lobe. Activity at the site of the lesion, in the long bones of the upper and lower limbs, rib cage, and vertebral bones was demonstrated by a bone scan. A CT-guided biopsy was performed, and the pathology report confirmed the presence of a leiomyoma. Following a right-sided lobectomy, the resected tumor was sent for histopathology, with the results confirming the biopsy. The patient subsequently presented with a history of persistent cough associated with increased watery secretions. The CT scan revealed the presence of a bronchopleural fistula, after which the patient underwent surgical correction. All symptoms resolved, and the patient was discharged in stable condition. CONCLUSIONS Here, we report on a patient who presented with 3 rare clinical findings: pulmonary leiomyoma, hypertrophic osteoarthropathy, and sterile bronchopulmonary fistula.
[Pt] Publication type:JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180309
[Lr] Last revision date:180309
[St] Status:In-Process

  3 / 21903 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29489700
[Au] Autor:Chen Q; Liu Q; Suo Y; Xie Q
[Ad] Address:Department of Hand Surgery, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou, Zhejiang, China.
[Ti] Title:A new surgical treatment for abdominal wall defects: A vascularized ribs-pleural transfer technique that can be used with or without a thoracic umbilical flap a case report.
[So] Source:Medicine (Baltimore);97(9):e9993, 2018 Mar.
[Is] ISSN:1536-5964
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:RATIONALE: Abdominal wall defects are common after tumor resection. PATIENT CONCERNS: We report an 83-year-old male patient with recurrent tumors in his abdomen, and who had an incision wound that could not be directly closed. Mesh was not suitable because the wound was infected. DIAGNOSES: Abdominal wall defect result from the resection of recurrent tumor. INTERVENTIONS: We carried out a vascularized ribs-pleural transfer operation. OUTCOMES: After the surgery, the patient gained a functional recovery. No evidence of recurrence was noted 1 year after operation, and the patient showed no symptoms of abdominal compression syndrome. LESSONS: We discuss the clinical diagnosis, treatment, and follow up and argue that the vascularized ribs-pleural transfer technique is a good method to deal with abdominal wall defects.
[Mh] MeSH terms primary: Abdominal Wall/surgery
Pleura/transplantation
Postoperative Complications/surgery
Reconstructive Surgical Procedures/methods
Ribs/transplantation
[Mh] MeSH terms secundary: Abdominal Neoplasms/surgery
Aged, 80 and over
Humans
Male
Neoplasm Recurrence, Local/surgery
Surgical Flaps
Umbilicus/transplantation
[Pt] Publication type:CASE REPORTS; JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180307
[Lr] Last revision date:180307
[Js] Journal subset:AIM; IM
[Da] Date of entry for processing:180301
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009993

  4 / 21903 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 28453802
[Au] Autor:Kostron A; Friess M; Inci I; Hillinger S; Schneiter D; Gelpke H; Stahel R; Seifert B; Weder W; Opitz I
[Ad] Address:Division of Thoracic Surgery, University Hospital Zurich, Zurich, Switzerland.
[Ti] Title:Propensity matched comparison of extrapleural pneumonectomy and pleurectomy/decortication for mesothelioma patients.
[So] Source:Interact Cardiovasc Thorac Surg;24(5):740-746, 2017 05 01.
[Is] ISSN:1569-9285
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:OBJECTIVES: The objective of this retrospective study was to assess perioperative outcomes, overall survival and freedom from recurrence after induction chemotherapy followed by extrapleural pneumonectomy (EPP) or pleurectomy/decortication (P/D) in patients with mesothelioma in a propensity score matched analysis. METHODS: Between September 1999 and August 2015, 167 patients received multimodality treatment (platinum-based chemotherapy followed by EPP [ n = 141] or P/D [ n = 26]). We performed 2:1 propensity score matching for gender, laterality, epithelioid histological subtype and International Mesothelioma Interest Group (iMig) stage (52 EPP and 26 P/D). RESULTS: Postoperative major morbidity (48% vs 58%, P = 0.5) was similar in both groups; however, the complication profile and severity were different and favoured P/D; the 90-day mortality (8% vs 0%, P = 0.3) rate was lower in P/D although not statistically significant. Prolonged air leak (≥10 days) occurred in 15 patients (58%) undergoing P/D. The intensive care unit stay was significantly longer after EPP ( P = 0.001). Freedom from recurrence was similar for both groups (EPP: median 15 months, 95% confidence interval [CI]: 10-21; P/D: 13 months, 95% CI: 11-17) ( P = 0.2). Overall survival was significantly longer for patients undergoing P/D (median 32 months, 95% CI: 29-35) compared to EPP (23 months, 95% CI: 21-25) ( P = 0.031), but in the P/D group many cases were censored (73%) and the follow-up time was relatively short. CONCLUSIONS: P/D and EPP seem to have similar rates of major morbidity, although the profile of complications is different and more severe after EPP. Freedom from recurrence is comparable in both groups whereas improved overall survival needs to be confirmed in a large patient group with longer follow-up.
[Mh] MeSH terms primary: Mesothelioma/surgery
Pleura/surgery
Pleural Neoplasms/surgery
Pneumonectomy/methods
Postoperative Complications/epidemiology
Propensity Score
[Mh] MeSH terms secundary: Adult
Aged
Female
Follow-Up Studies
Humans
Male
Mesothelioma/diagnosis
Middle Aged
Morbidity/trends
Neoplasm Recurrence, Local/epidemiology
Pleural Neoplasms/diagnosis
Retrospective Studies
Survival Rate/trends
Switzerland/epidemiology
Time Factors
Treatment Outcome
[Pt] Publication type:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Em] Entry month:1709
[Cu] Class update date: 180308
[Lr] Last revision date:180308
[Js] Journal subset:IM
[Da] Date of entry for processing:170429
[St] Status:MEDLINE
[do] DOI:10.1093/icvts/ivw422

  5 / 21903 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29223272
[Au] Autor:Linnik YA; Hoegemann Savellano D; Phillips JD; Black CC
[Ad] Address:Department of Pathology and Laboratory Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, NH. Electronic address: yevgeniy.a.linnik@hitchcock.org.
[Ti] Title:A 49-Year-Old Woman With Right Apical Thoracic Mass.
[So] Source:Chest;152(6):e133-e138, 2017 12.
[Is] ISSN:1931-3543
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:A 49-year-old woman with a medical history of essential hypertension presented to the ED with severe pain in the left superior chest and dull aching pain in the upper flank, lasting for the last 2 days.
[Mh] MeSH terms primary: Ganglioneuroma/diagnosis
Mediastinal Neoplasms/diagnosis
Thoracoscopy/methods
[Mh] MeSH terms secundary: Diagnosis, Differential
Female
Ganglioneuroma/surgery
Humans
Magnetic Resonance Imaging
Mediastinal Neoplasms/surgery
Middle Aged
Radiography, Thoracic
Robotic Surgical Procedures/methods
Tomography, X-Ray Computed
[Pt] Publication type:CASE REPORTS; JOURNAL ARTICLE
[Em] Entry month:1712
[Cu] Class update date: 180305
[Lr] Last revision date:180305
[Js] Journal subset:AIM; IM
[Da] Date of entry for processing:171211
[St] Status:MEDLINE

  6 / 21903 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 28460459
[Au] Autor:Inaguma S; Wang Z; Lasota J; Onda M; Czapiewski P; Langfort R; Rys J; Szpor J; Waloszczyk P; Okon K; Biernat W; Ikeda H; Schrump DS; Hassan R; Pastan I; Miettinen M
[Ad] Address:Laboratory of Pathology, National Cancer Institute, Bethesda, MD, USA.
[Ti] Title:Comprehensive immunohistochemical study of mesothelin (MSLN) using different monoclonal antibodies 5B2 and MN-1 in 1562 tumors with evaluation of its prognostic value in malignant pleural mesothelioma.
[So] Source:Oncotarget;8(16):26744-26754, 2017 Apr 18.
[Is] ISSN:1949-2553
[Cp] Country of publication:United States
[La] Language:eng
[Ab] Abstract:Mesothelin (MSLN) is a glycophosphatidylinositol (GPI)-linked cell surface protein highly expressed in several types of malignant tumors sometimes in association with increased tumor aggressiveness and poor clinical outcome. In the present study, 1562 tumors were immunohistochemically analyzed for mesothelin expression using two different types of mouse monoclonal antibodies (5B2 and MN-1) to determine the clinical usefulness of mesothelin immunohistochemistry as well as to pinpoint potential targets for future anti-mesothelin therapy. Also, characterization of selected mesothelin-positive tumors was performed by immunohistochemistry and oncogene sequencing. Among the tumors analyzed, the highest frequencies of mesothelin-positivity were detected in ovarian serous carcinoma (90% in 5B2 and 94% in MN-1). Both antibodies showed frequent positivity in pancreatic adenocarcinoma (71% using 5B2 and 87% using MN-1) and malignant pleural mesothelioma (75% using 5B2 and 78% using MN-1). In malignant mesothelioma, overall survival was significantly longer in the cohort of patients with diffuse membranous expression of mesothelin (P < 0.001). Both antibodies showed positive staining in thymic carcinoma (77% in 5B2 and 59% in MN-1), however, no expression was detected in thymoma. No correlation was detected between mesothelin expression and mismatch repair system deficient phenotype or gene mutation (BRAF and RAS) status in gastrointestinal adenocarcinomas. Mesothelin immunohistochemistry may assist the differential diagnosis of thymoma vs. thymic carcinoma as well as prognostication of mesothelioma patients. Our results demonstrate that patients with solid tumors expressing mesothelin could be targeted by anti-mesothelin therapies.
[Mh] MeSH terms primary: Biomarkers, Tumor
GPI-Linked Proteins/metabolism
Lung Neoplasms/metabolism
Lung Neoplasms/mortality
Mesothelioma/metabolism
Mesothelioma/mortality
Pleural Neoplasms/metabolism
Pleural Neoplasms/mortality
[Mh] MeSH terms secundary: Antibodies, Monoclonal
Diagnosis, Differential
Gene Expression
Humans
Immunohistochemistry
Lung Neoplasms/diagnosis
Lung Neoplasms/genetics
Mesothelioma/diagnosis
Mesothelioma/genetics
Mutation
Pleural Neoplasms/diagnosis
Pleural Neoplasms/genetics
Prognosis
Survival Analysis
[Pt] Publication type:JOURNAL ARTICLE
[Nm] Name of substance:0 (Antibodies, Monoclonal); 0 (Biomarkers, Tumor); 0 (GPI-Linked Proteins); 0 (mesothelin)
[Em] Entry month:1803
[Cu] Class update date: 180305
[Lr] Last revision date:180305
[Js] Journal subset:IM
[Da] Date of entry for processing:170503
[St] Status:MEDLINE
[do] DOI:10.18632/oncotarget.15814

  7 / 21903 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy
Full text

[PMID]: 29502371
[Au] Autor:Wang X; Xu YH; Du ZY; Qian YJ; Xu ZH; Chen R; Shi MH
[Ad] Address:Department of Respiration, Second Affiliated Hospital to Soochow University, Suzhou 215000, China.
[Ti] Title:[Risk factor analysis of the patients with solitary pulmonary nodules and establishment of a prediction model for the probability of malignancy].
[So] Source:Zhonghua Zhong Liu Za Zhi;40(2):115-120, 2018 Feb 23.
[Is] ISSN:0253-3766
[Cp] Country of publication:China
[La] Language:chi
[Ab] Abstract:This study aims to analyze the relationship among the clinical features, radiologic characteristics and pathological diagnosis in patients with solitary pulmonary nodules, and establish a prediction model for the probability of malignancy. Clinical data of 372 patients with solitary pulmonary nodules who underwent surgical resection with definite postoperative pathological diagnosis were retrospectively analyzed. In these cases, we collected clinical and radiologic features including gender, age, smoking history, history of tumor, family history of cancer, the location of lesion, ground-glass opacity, maximum diameter, calcification, vessel convergence sign, vacuole sign, pleural indentation, speculation and lobulation. The cases were divided to modeling group (268 cases) and validation group (104 cases). A new prediction model was established by logistic regression analying the data from modeling group. Then the data of validation group was planned to validate the efficiency of the new model, and was compared with three classical models(Mayo model, VA model and LiYun model). With the calculated probability values for each model from validation group, SPSS 22.0 was used to draw the receiver operating characteristic curve, to assess the predictive value of this new model. 112 benign SPNs and 156 malignant SPNs were included in modeling group. Multivariable logistic regression analysis showed that gender, age, history of tumor, ground -glass opacity, maximum diameter, and speculation were independent predictors of malignancy in patients with SPN( <0.05). We calculated a prediction model for the probability of malignancy as follow: =e(x)/(1+ e(x)), x=-4.8029-0.743×gender+ 0.057×age+ 1.306×history of tumor+ 1.305×ground-glass opacity+ 0.051×maximum diameter+ 1.043×speculation. When the data of validation group was added to the four-mathematical prediction model, The area under the curve of our mathematical prediction model was 0.742, which is greater than other models (Mayo 0.696, VA 0.634, LiYun 0.681), while the differences between any two of the four models were not significant ( >0.05). Age of patient, gender, history of tumor, ground-glass opacity, maximum diameter and speculation are independent predictors of malignancy in patients with solitary pulmonary nodule. This logistic regression prediction mathematic model is not inferior to those classical models in estimating the prognosis of SPNs.
[Pt] Publication type:ENGLISH ABSTRACT; JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180305
[Lr] Last revision date:180305
[St] Status:In-Process
[do] DOI:10.3760/cma.j.issn.0253-3766.2018.02.007

  8 / 21903 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy

[PMID]: 29361626
[Au] Autor:Asai M; Tanaka H; Goto Y; Yamada T; Yuasa N; Takeuchi E; Miyake H; Nagai H; Yoshioka Y; Okuno M; Kawai N; Minami T; Nagao T; Maeda S; Mouri K; Fukata K; Mizuno H; Iwase T; Miyata K
[Ad] Address:Dept. of Surgery, Japanese Red Cross Nagoya Daiichi Hospital.
[Ti] Title:[Secondary Dementia Due to Leptomeningeal Metastasis of Breast Cancer Improved by Whole Brain Radiation].
[So] Source:Gan To Kagaku Ryoho;44(13):2101-2103, 2017 Dec.
[Is] ISSN:0385-0684
[Cp] Country of publication:Japan
[La] Language:jpn
[Ab] Abstract:A 62-year-old woman received chemotherapy for breast cancer with bone metastasis and malignant pleural and pericardial effusion. She was examined by imaging for progressive cognitive impairment and headache. Enhanced MRI findings showed multiple solid tumors on brain surface, and brain perfusion scintigraphy showed blood flow decrease in both parietal lobes. She was diagnosed with secondary dementia due to leptomeningeal metastases of breast cancer, and whole brain external irradiation was performed(30 Gy/15 Fr). After treatment, multiple tumors were decreased in size and her cognitive impair- ment was improved.
[Mh] MeSH terms primary: Brain Neoplasms/radiotherapy
Breast Neoplasms/pathology
Dementia/etiology
Meningeal Neoplasms/radiotherapy
[Mh] MeSH terms secundary: Brain Neoplasms/diagnostic imaging
Brain Neoplasms/secondary
Female
Humans
Magnetic Resonance Imaging
Meningeal Neoplasms/diagnostic imaging
Meningeal Neoplasms/secondary
Middle Aged
[Pt] Publication type:CASE REPORTS; JOURNAL ARTICLE
[Em] Entry month:1803
[Cu] Class update date: 180302
[Lr] Last revision date:180302
[Js] Journal subset:IM
[Da] Date of entry for processing:180124
[St] Status:MEDLINE

  9 / 21903 MEDLINE  
              first record previous record next record last record
select
to print
Photocopy

[PMID]: 29361614
[Au] Autor:Nakano T
[Ad] Address:Division of Respiratory Medicine, Dept. of Internal Medicine, Otemae Hospital.
[Ti] Title:[Systemic Treatment of Malignant Pleural Mesothelioma].
[So] Source:Gan To Kagaku Ryoho;44(13):2041-2047, 2017 Dec.
[Is] ISSN:0385-0684
[Cp] Country of publication:Japan
[La] Language:jpn
[Ab] Abstract:Malignant pleural mesothelioma(MPM)is a highly aggressive tumor with a poor prognosis and an increasing incidence worldwide. The only standard first-line chemotherapy for patients with unresectable MPM is cisplatin(CDDP)plus peme- trexed(PEM)(CDDP/PEM), with a median overall survival of about 12months and a median progression-free survival(PFS) of less than 6 months. There are no treatments with proven benefit on survival for relapsed MPM patients. Therefore, novel therapeutic strategies are urgently required. Several molecular pathways involved in MPM have been identified; these include growth factor signaling pathways, cell cycle regulation, apoptosis, and angiogenesis. Fortunately, several agents targeting these processes have yielded promising results in preliminary trials. The addition of vascular endothelial growth factor(VEGF) inhibitor bevacizumab to the standard CDDP/PEM provides a 2.7-month survival benefit. Triple angiokinase inhibitor nintedanib, inhibiting the VEGFR, PDGFR, and FGFR, plus standard chemotherapy demonstrated a significant improvement in median PFS of 3.7 months in the overall study population, and a greater median PFS benefit of 4.0 months in epithelioid MPM. Mesothelin is an attractive target protein expressed on mesothelioma cells. Amatuximab, a chimeric anti-mesothelin antibody, in combination with CDDP/PEM, is currently being tested in randomized, double-blind, placebo-controlled phase II study. Anetumab ravtansine, mesothelin-directed antibody drug conjugate, was evaluated in a randomized trial to compare to vinorelbine in patients with MPM who have high mesothelin expression and have progressed on CDDP/PEM-based first-line chemotherapy. However, anetumab ravtansine was not superior to vinorelbine in primary endpoint of PFS(4.3 months vs 4.5 months). Immune checkpoint blockades have demonstrated promising preclinical and clinical results in several cancer types, and are currently being investigated in clinical trials for MPM patients. PD-L1 expression in tumor tissue of MPM was reported, ranging between 20% and 70%. PD-L1 expression was significantly associated with a worse survival and overexpression was more common in sarcomatoid histology. This review summarizes clinical results for the latest systemic treatments in MPM.
[Mh] MeSH terms primary: Antineoplastic Agents/therapeutic use
Lung Neoplasms/drug therapy
Mesothelioma/drug therapy
Pleural Neoplasms/drug therapy
[Mh] MeSH terms secundary: Humans
Lung Neoplasms/blood supply
Mesothelioma/blood supply
Neovascularization, Pathologic
Pleural Neoplasms/blood supply
Pleural Neoplasms/pathology
[Pt] Publication type:JOURNAL ARTICLE; REVIEW
[Nm] Name of substance:0 (Antineoplastic Agents)
[Em] Entry month:1803
[Cu] Class update date: 180302
[Lr] Last revision date:180302
[Js] Journal subset:IM
[Da] Date of entry for processing:180124
[St] Status:MEDLINE

  10 / 21903 MEDLINE  
              first record previous record
select
to print
Photocopy
Full text

[PMID]: 29300072
[Au] Autor:Igai H; Kamiyoshihara M; Kawatani N; Shimizu K
[Ad] Address:Department of General Thoracic Surgery, Maebashi Red Cross Hospital 3-21-36 Asahi-cho, Maebashi, Gunma 371-0014, Japan.
[Ti] Title:Thoracoscopic right upper lobectomy after an initial anatomic pulmonary resection of the lower lobe.
[So] Source:Multimed Man Cardiothorac Surg;2017, 2017 Nov 14.
[Is] ISSN:1813-9175
[Cp] Country of publication:England
[La] Language:eng
[Ab] Abstract:It is challenging to redo an anatomical pulmonary resection on the ipsilateral side because of the adhesions or dense fissures caused by the initial anatomic pulmonary resection. Few reports describe surgical techniques for addressing these challenges, especially using a minimally invasive thoracoscopic approach instead of standard thoracotomy. Here, we demonstrate a thoracoscopic right upper lobectomy after an initial anatomic pulmonary resection of the right lower lobe and explain the nuances of performing it.
[Mh] MeSH terms primary: Lung Neoplasms/surgery
Pneumonectomy/methods
Thoracoscopy
[Mh] MeSH terms secundary: Humans
Pneumonectomy/adverse effects
Reoperation
Tissue Adhesions/etiology
Tissue Adhesions/surgery
[Pt] Publication type:VIDEO-AUDIO MEDIA
[Em] Entry month:1803
[Cu] Class update date: 180302
[Lr] Last revision date:180302
[Js] Journal subset:IM
[Da] Date of entry for processing:180105
[St] Status:MEDLINE
[do] DOI:10.1510/mmcts.2017.014


page 1 of 2191 go to page                         
   


Refine the search
  Database : MEDLINE Advanced form   

    Search in field  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/PAHO/WHO - Latin American and Caribbean Center on Health Sciences Information